Epidemiology of genital herpes simplex virus infections in a community-based sample in France: Results of the HERPIMAX study

Sexually Transmitted Diseases

Volumn 32, Issue 8, 2005, Pages 499-505

  Malvy, Denis ^a   Halioua, Bruno ^b   Lançon, Florian ^c   Rezvani, Ali ^d   Bertrais, Sandrine ^d   Chanzy, Bruno ^e   Daniloski, Michel ^c   Ezzedine, Khaled ^f   Malkin, Jean Elie ^g   Morand, Patrice ^h   De Labareyre, Cecile ^c   Hercberg, Serge ^d   El Hasnaoui, Abdelkader ^c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT ALFRED FOURNIER   (France)

^c GLAXOSMITHKLINE   (France)

^d Bioinformatique et Chimie Moléculaire   (France)

^e Virology Laboratory   (France)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g INSTITUT PASTEUR   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FATIGUE; FEMALE; FRANCE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; QUESTIONNAIRE; RECURRENT INFECTION; RISK FACTOR; SEROPREVALENCE; SEXUAL INTERCOURSE; STATISTICAL ANALYSIS; STRESS; SWEATING;

EID: 23044507039     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000161188.82905.b7     Document Type: Article

References (33)

1. Nahmias AJ, Lee FK, Beckman-Namias S. Seroepidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990; 69:19-36.
2. Brugha R, Keersmaekers K, Renton A, Meheus A. Genital herpes infection: A review. Int J Epidemiol 1997; 26:698-709.
3. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: A global review. J Infect Dis 2002; 186(suppl 1): S3-S28.
4. Johnson RE, Nahmias AJ, Magder LS, et al. A seroepidemiological survey of prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321:7-12.
5. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111.
6. Halioua B, Malkin JE. Epidemiology of genital herpes-Recent advances. Eur J Dermatol 1999; 9:177-184.
7. Kinghorn GR. Epidemiology of genital herpes. J Int Med Res 1994; 22(suppl 1):14-23.
8. Chuang T, Su WPD, Perry HO, et al. Incidence and trend of herpes progenitalis: A 15-year population study. Mayo Clin Proc 1983; 58:436-441.
9. Armstrong GL, Schillinger J, Markowitz L, et al. Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001; 153:912-920.
10. Patel R. Genital herpes in Europe. J Eur Acad Dermatol Venereol 2002; 16(suppl 1):8.
11. Rabenau HF, Buxbaum S, Preiser W, et al. Seroprevalence of herpes simplex virus type 1 and type 2 in the Frankfurt am Main area, Germany. Med Microbiol Immunol 2002; 190:153-160.
12. Hercberg S, Galan P, Preziosi P, et al. Background and rationale behind the SU.VI.MAX study, a prevention trial using nutritional doses of antioxidant vitamins and minerals to reduce cardio-vascular diseases and cancers. Supplementation en Vitamines et Minéraux AntioXydants Study. Int J Vitam Nutr Res 1998; 68:3-20.
13. Hercberg S, Preziosi P, Briançon S, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals on cardiovascular diseases and cancers in general population: the SU.VI.MAX study - Design, methods and participant characteristics control. Supplementation en Vitamines et Minéraux AntioXydants Study. Control Clin Trials 1998; 19:336-351.
14. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: Aa randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164: 2335-2342.
15. Malkin JE, Morand P, Malvy D, et al. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sex Transm Infect 2002; 78:201-203.
16. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002; 185:1019-1024.
17. Bunzli D, Wietlisbach V, Barazzoni F, et al. Seroepidemiology of herpes simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: A population-based study. BMC Infect Dis 2004; 4:10.
18. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131:14-20.
19. Diamond C, Selke S, Ashley R, et al. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis 1999; 26: 221-225.
20. AIDS surveillance in France. Bulletin Epidémiologique Hebdomadaire 2001; No. 24.
21. Oliver L, Wald A, Kim M, et al. Seroprevalence of herpes simplex virus infections in a family medicine clinic. Arch Family Med 1995; 4:228-232.
22. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-437.
23. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
24. Vyse AJ, Gay NJ, Slomka MJ, et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: Implications for the changing epidemiology of genital herpes. Sex Transm Infect 2000; 76:183-187.
25. Hashido M, Lee FK, Nahmias AJ, Kawana T. Prevalence of herpes simplex virus type 1- and 2-specific antibodies among the acute, recurrent, and provoked types of female genital herpes. Microbiol Immunol 1997; 41:823-827.
26. Lowhagen GB, Tunback P, Bergstrom T. Proportion of herpes simplex virus (HSV) type 1 and type 2 among genital and extragenital HSV isolates. Acta Derm Venereol 2002; 82:118-120.
27. Samra Z, Scherf E, Dan M. Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel. Sex Transm Dis 2003; 30:794-796.
28. Ribes JA, Steele AD, Seabolt JP, Baker DJ. Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol 2001; 39:3321-3325.
29. Johnsson MK, Wahren B. Sexually transmitted herpes simplex viruses. Scand J Infect Dis 2004; 36:93-101.
30. Ashley RL. Herpes simplex viruses. In: Schmidt NJ, Lennette DA, Lennette ET, Lennette EH, Emmons RW, eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. American Public Health Association. 1995; 22:375-378.
31. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432-1438.
32. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-1661.
33. Gottlieb SL, Douglas JM Jr., Schmid DS, et al. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J Infect Dis 2002; 186:1381-1389.